What are ASCO/OH(CCO) recommendations for systemic treatment of stage IV non–small cell lung cancer (NSCLC) in patients with BRAF mutations?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print
Answer

See the list below:

  • For first-line therapy in patients with the  BRAF V600E mutation, dabrafenib/trametinib or standard treatment for NSCLC without driver mutations may be offered.
  • For second-line therapy in patients with the  BRAF V600E mutation who received BRAF/MEK-targeted therapy (dabrafenib/trametinib) in the first-line setting, standard treatment for NSCLC without driver mutations should be offered.
  • For second-line therapy in patients who did not receive BRAF-targeted therapy in the first-line setting, dabrafenib/trametinib or dabrafenib or vemurafenib alone may be offered.
  • For second-line therapy in patients with BRAF mutations other than V600E, standard treatment for NSCLC without driver mutations should be offered.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!